Table 1 Study characteristics of the included studies
Author | Year | Design | Patients (n) | Inclusion | Neoadjuvant therapy regimen | Scanner | FDG dose (MBq) | Uptake time (min) | Median follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|
Akimoto [12] | 2018 | P | 130 | Not specified | Anthracycline + taxane-based | PET/CT | 3.7/kg | 60 | NR |
Champion [13] | 2015 | P | 23 | Inflammatory | Anthracycline ± taxane-based | PET/CT | 4–5/kg | 73 ± 21 | 76 ± 27 |
Chen [14] | 2017 | R | 86 | Stage II–III | Anthracycline ± taxane-based | PET/CT | 259–555 | 60 | 71 (8–118) |
Dunnwald [15] | 2011 | P | 75 | LABC | Anthracycline ± taxane-based | PET | 218–399 | 60 | DFS: 50 (1–156) OS: 60 (7–161) |
Emmering [16] | 2008 | P | 40 | LABC | Anthracycline-based | PET | 370 | 60–90 | 60 |
Garcia Vicente [17] | 2016 | P | 132 | Not specified | Anthracycline ± taxane-based | PET/CT | 370 | 60 | 35.5* (12–62) |
Groheux [18] | 2015 | P | 82 | ER+/HER2−, stage II–III | Anthracycline + taxane-based | PET/CT | 5/kg | 60 | 35 (10–71) |
Groheux [19] | 2016 | R | 78 | TN, stage II–III | Anthracycline + taxane-based; dose-intense anthracycline-based | PET/CT | 5/kg | 60 | 34 (3–85) |
Humbert [20] | 2014 | P | 42 | HR+/HER2−, stage II–IIIA | Anthracycline ± taxane-based | PET or PET/CT | PET: 2/kg; PET/CT: 5/kg | 60 | 64.2 (11.5–93.2) |
Humbert [21] | 2016 | P | 46 | TN, Stage II–III | Anthracycline ± taxane-based | PET/CT | 5/kg | 60 | 30 (6–73) |
Hyun [22] | 2015 | R | 167 | Stage II–III | Anthracycline ± taxane-based | PET/CT | 5.5/kg | 60 | 19 (3–85) |
Ishiba [23] | 2015 | R | 83 | Not specified | Anthracycline ± taxane-based | PET/CT | 3.7/kg | NR | 50 |
Jung [24] | 2010 | P | 66 | Stage II–III | Anthracycline ± taxane-based | PET | 370–555 | 60 | 61.5 (13.5–71.8) |
Kim [25] | 2016 | R | 139 | Stage II–III | Anthracycline + taxane-based | PET/CT | 5/kg | 60 | 26.2 ± 16.1* |
Kitajima [26] | 2018 | R | 56 | Not specified | Anthracycline ± taxane-based | PET/CT | 3–4/kg | 60 | No recurrence: 29.1 (12.3–96.4) Recurrence: 19.2 (11.4–37.4) |
Kiyoto [27] | 2016 | R | 32 | TN, stage II–III | Anthracycline ± taxane-based | PET/CT | 3/kg | 90 | 39.0 (5.8–91.2) |
Kolesnikov-Gauthier [28] | 2012 | P | 60 | Non-inflammatory, M0 | Anthracycline + taxane-based | PET | 370 | 60 | 43 (14–68) |
Lee [29] | 2016 | R | 87 | Stage II–III | Anthracycline-based | PET or PET/CT | 5.5/kg | 60 | 61 (10–107) |
Lian [30] | 2020 | R | 92 | Not specified | Anthracycline ± taxane ± platinum-based | PET/CT | 7.4/kg | 60 | No recurrence: 48.7 (20.6–84.1) Recurrence: 38.6 (11.4–82.7) |
Lim [31] | 2014 | P | 54 | Stage II–III | Anthracycline + taxane-based | PET/CT | 7.4/kg | 60 | 38 (25–45) |
Zucchini [32] | 2013 | R | 60 | Early, LABC, or oligometastatic | Anthracycline + taxane-based | PET/CT | 5.3/kg | 60–70 | 36.6 (8–79) |